Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.59 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.55 |
| ▸ | BRAF | P15056 | 2/20 | 0.51 |
| ▸ | FYN | P06241 | 3/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.47 |
| ▸ | PLAU | P00749 | 2/20 | 0.47 |
| ▸ | PLAT | P00750 | 2/20 | 0.47 |
| ▸ | PLG | P00747 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4187491 | 0.85 | XDH (0.57) | XDHSLC22A12CYP11B2BRAFFYN | |
| SCHEMBL4148171 | 0.84 | MAP4K4 (0.52) | MAP4K4CYP11B1CYP11B2FYNMKNK1 | |
| SCHEMBL4199231 | 0.84 | XDH (0.57) | XDHSLC22A12MAP4K4FYNMKNK1 | |
| SCHEMBL4184883 | 0.84 | BRAF (0.71) | CYP11B1CYP11B2BRAFFYNMKNK1 | |
| SCHEMBL2820197 | 0.83 | ADORA3 (0.69) | XDHSLC22A12BRAFFYNCYP1A2 | |
| SCHEMBL4183159 | 0.83 | FYN (0.55) | XDHSLC22A12BRAFFYNCYP1A2 | |
| SCHEMBL30834601 | 0.82 | SIRT2 (0.63) | XDHSLC22A12MAP4K4CYP11B1CYP11B2 | |
| SCHEMBL3662153 | 0.82 | MKNK1 (0.72) | MAP4K4CYP11B1CYP11B2FYNMKNK1 | |
| SCHEMBL4198997 | 0.82 | BRAF (0.72) | XDHSLC22A12BRAFFYN | |
| SCHEMBL4182331 | 0.82 | SIRT2 (0.71) | XDHSLC22A12CYP11B1CYP11B2FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | claimed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | claimed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | claimed |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | disclosed |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | BROWN DENNIS M (US) | 2019-08-20 | — | — | US | disclosed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | disclosed |
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | disclosed |
| US-20090163515-A1 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | BIOFOCUS DISCOVERY LTD. | 2009-06-25 | — | — | US | disclosed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163515-A1 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | ROCK1, ROCK2, CIT | XDH 750/4885SLC22A12 4511/4885MAP4K4 75/4885 |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | NEK9, NEK7, NEK3 | XDH 1630/4885SLC22A12 3973/4885MAP4K4 546/4885 |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | XDH 1630/4885SLC22A12 3973/4885MAP4K4 546/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | XDH 1630/4885SLC22A12 3973/4885MAP4K4 546/4885 |
| US-20090196912-A1 | Pyridinylamines | PRNP, PLPBP, SNCA | XDH 527/4885SLC22A12 2928/4885MAP4K4 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.